Print
Advertisement
The anti-CD19 autologous CAR-T-cell therapy was approved for use in adults with relapsed or refractory disease.
The new indication for daratumumab and hyaluronidase-fihj plus D-VRd is based on results from the phase II CEPHEUS study.
The approval is based on results from the phase I ELM-1 and phase II ELM-2 trials.
Following FDA approval, luspatercept and imetelstat are propelling the MDS treatment landscape forward.
The hospital's cellular therapy and transplant section will provide an education plan for Sidra Medicine’s clinical staff.
Myeloma experts are advocating for dose reductions of bortezomib due to improved safety and comparable efficacy.
Advertisement
Dr. DeZern discusses how medicine has changed and shares some advice for early-career clinicians.
The approval is based on results of the randomized, open-label, multicenter AGAVE-201 trial.
The conditional marketing authorization was given for use as monotherapy in adults after two or more lines of prior therapy.
In an ongoing, phase I/II trial, DSP-5336 achieved an objective response rate of 57% and a CR/CRh rate of 24%.
The approval is based on results from the PERSEUS trial, in which D-VRd achieved deeper responses when compared with VRd.
Multivariable analysis in a phase II study linked the supplements to an overall survival benefit in patients.
Dr. Unni is an Associate Professor in the Department of Internal Medicine at the UT Southwestern Medical Center.
Tafasitamab is a humanized, Fc-modified monoclonal antibody that targets the CD19 antigen.
The NMPA approval for adult patients was based on the results from the multinational JACKPOT8 Part B study.
The approval was based on results from the EPCORE® NHL-1 trial, in which epcoritamab achieved an ORR of 82%.
ESA treatment after red blood cell transfusions was associated with worse survival compared with ESAs prior to transfusions.
Dr. Berger served as Founding Director of the Case Comprehensive Cancer Center before his passing on June 15, 2024.
A reduced venetoclax exposure of seven days was comparable with continual venetoclax exposure in patients with AML.
The Humanitarian Award recognizes oncologists who exemplify outstanding patient care and voluntary humanitarian endeavors.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.